skip to content

eLesor Investments version="1.1" id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 697.5 99.8" style="enable-background:new 0 0 697.5 99.8;" xml:space="preserve" aria-labelledby="title--mwlogoHeader desc--mwlogoHeader" role="img"> eLesor Site Logo A link that brings you back to the homepage.

Acorda Therapeutics Shares up After Deal to Commercialize Inbrija in Spain

By Stephen Nakrosis

Shares of Acorda Therapeutics Inc. are trading higher in Thursday's after-hours market, following the company's announcement it entered agreements with Esteve Pharmaceuticals S.A to commercialize Inbrija 33 mg in Spain.

Acorda said it will supply Inbrija and receive a "significant double-digit percent" of the selling price in Spain.

At 6:05 p.m. ET, the company's shares were trading 24.67% higher at $4.75. Volume at the time topped 645,000 shares.

The company's stock finished the day's regular-trading session with a 45.27% loss, closing at $3.81.

Write to Stephen Nakrosis at [email protected]




      

Partner Center